Philip Morris International's US Launch of Zyn Ultra Seen as Potential Catalyst, Morgan Stanley Says

MT Newswires Live06-03 23:09

Philip Morris International's (PM) launch of Zyn Ultra nicotine pouches in the US will be a potential catalyst for the stock, Morgan Stanley said in a note emailed Wednesday.

In an investor conference Tuesday, the company said it is launching Zyn Ultra in the US this month in 9- and 11-milligram strengths across a range of flavors similar to the original Zyn offerings, which was largely expected after the Food and Drug Administration's new enforcement guidance for nicotine pouches and e-vapor products, according to the note.

Philip Morris also stated that its heat-not-burn category in Japan has been roughly matching its expectations, with IQOS holding its market share even after a significant excise tax-driven price increase on April 1, the firm noted.

Morgan Stanley said it projected above-consensus growth for the stock in the medium term driven by the continued momentum of IQOS globally, the Zyn Ultra launch pushing US growth, and the planned roll-out of IQOS ILUMA in the US.

Morgan Stanley maintained the company's stock rating at overweight and raised the price target to $200 from $190.

Price: 176.41, Change: +2.75, Percent Change: +1.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment